Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QAX576 proof-of-concept study in seasonal allergic rhinitis after repeated nasal Timothy grass allergen challenge
2007-003403-13Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) comparing QAX576 with Placebo (2 arms). Primary endpoint: IL-5 concentration in nasal secretions. Started Sep 2007; status: completed.
02
Drugs
dectrekumab
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2007-003403-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003403-13.